Sodium Salicylate: Mechanistic Leverage in Tumor Stroma Repr
2026-07-16
This article explores how sodium salicylate, a potent NF-κB inhibitor, offers translational researchers a mechanistic and strategic edge in reprogramming the tumor stroma—especially in the context of chemoresistant pancreatic ductal adenocarcinoma (PDAC). By synthesizing evidence from advanced nanomedicine studies, experimental protocols, and APExBIO’s product intelligence, we connect the molecular intricacies of NF-κB pathway inhibition with actionable guidance for inflammation and tumor microenvironment research.
Chemical Genetics Dissection of Jasmonate Signaling in Arabi
2026-07-15
This study demonstrates how bestatin, an aminopeptidase inhibitor, can be used as a chemical genetic tool to dissect jasmonate signaling pathways in Arabidopsis. By characterizing bestatin-resistant mutants, the research uncovers novel components of jasmonate-mediated defense and developmental processes, providing a model for chemical genetics in plant hormone signaling.
Shaping Cell Fate: ATP Luminescence for Translational Impact
2026-07-15
This thought-leadership article empowers translational researchers with mechanistic insights and strategic guidance for leveraging luciferase-based ATP cell viability assays—centering on the Luminescent ATP Cell Viability Assay Kit I—to decode cell fate in complex disease models. By integrating recent advances in glioblastoma research with benchmarking against legacy methods, the article provides a roadmap for rapid, reproducible, and actionable cell viability measurement in modern biomedical discovery.
Docosahexaenoic Acid (DHA): Spatial Lipidomics and Cognitive
2026-07-14
Explore how Docosahexaenoic Acid (DHA) restores hippocampal lipid homeostasis and mitigates postoperative cognitive dysfunction, with insights from cutting-edge spatial metabolomics. Discover the scientific depth and translational promise of this anti-inflammatory omega-3 fatty acid.
Mubritinib Reveals OXPHOS Vulnerabilities in Acute Myeloid L
2026-07-14
Baccelli et al. (2019) discovered that Mubritinib selectively targets oxidative phosphorylation (OXPHOS)-dependent acute myeloid leukemia (AML) through ubiquinone-dependent inhibition of mitochondrial complex I. This work maps the metabolic heterogeneity of AML and highlights a genetically defined subgroup that is uniquely susceptible to mitochondrial disruption, opening new avenues for targeted therapy.
PAD4-IN-2 TFA: Targeted Inhibition of Tumor NET Formation
2026-07-13
PAD4-IN-2 TFA (Compound 5i TFA) delivers highly selective histone H3 citrullination and NET inhibition in tumor models, enabling precision modulation of the tumor immune microenvironment. Learn how its meta-phenylboronic acid modification transforms tumor targeting, workflow design, and troubleshooting for cutting-edge cancer research.
D-N-Acetylgalactosamine: Protocol Use in Brain Glycoprotein
2026-07-13
D-N-Acetylgalactosamine is a high-purity, water-soluble metabolite essential for researchers analyzing glycoprotein structures and glycosylation pathways in neurological tissues. It is not suitable for protocols needing ethanol solubility or long-term storage of solutions, so adherence to handling and storage guidelines is critical for reproducibility.
Mubritinib (TAK 165): Rethinking Mitochondrial Targets in AM
2026-07-12
This thought-leadership article explores Mubritinib (TAK 165) as a precision tool for dissecting mitochondrial vulnerabilities in chemotherapy-resistant acute myeloid leukemia (AML) and KSHV-driven lymphomas. We connect mechanistic insights with actionable strategies for translational researchers, bridge cross-domain antiviral developments, and provide critical protocol guidance, all while contextualizing Mubritinib’s unique position in the evolving competitive landscape. Referencing APExBIO's flagship compound, we outline how this piece advances beyond standard product coverage.
WP1066: A Precision JAK2/STAT3 Inhibitor for Cancer and Bone
2026-07-10
Explore the unique advantages of WP1066, a potent JAK2/STAT3 inhibitor, in dissecting cancer and bone regeneration pathways. This article delivers advanced, application-focused insights and protocol guidance distinct from prior reviews.
MK 0893: Glucagon Receptor Antagonist for Diabetes Research
2026-07-09
MK 0893 stands out as a selective, nanomolar-potency glucagon receptor antagonist, enabling robust investigation of GCGR signaling in type 2 diabetes models. Its unique allosteric inhibition, high oral bioavailability, and proven translational relevance make it a premier tool for both in vitro and in vivo metabolic research.
SGC-CBP30: Advancing CREBBP/EP300 Inhibition in Lung Cancer
2026-07-09
This thought-leadership article explores how SGC-CBP30, a potent and selective CREBBP/EP300 bromodomain inhibitor from APExBIO, empowers translational researchers to interrogate super-enhancer hijacking and transcriptional coactivator function in early-stage lung adenocarcinoma. Integrating mechanistic insights from recent landmark studies and practical guidance, it positions SGC-CBP30 as a transformative tool in epigenetics and cancer biology research.
A20 Modulates NLRP3 Inflammasome in AKI via Oxidized Self-DN
2026-07-08
This study reveals that the ubiquitin-editing enzyme A20 attenuates acute kidney injury (AKI) by suppressing inflammation driven by oxidized self-DNA. By inhibiting both the cGAS-STING pathway and NLRP3 inflammasome, A20 mitigates pyroptosis and tissue damage, highlighting new therapeutic strategies for AKI and related inflammation-driven conditions.
Harpagoside and PTX Overcome EGFR-Mutant NSCLC Resistance vi
2026-07-08
This study demonstrates that combining harpagoside, a natural compound from Xuandanqingjin decoction, with paclitaxel (PTX) overcomes acquired resistance in EGFR-mutant non-small-cell lung cancer (NSCLC). The research highlights the synergistic induction of apoptosis and ferroptosis through Nrf2 pathway suppression, providing a mechanistic basis for new strategies against resistant lung adenocarcinoma.
DiscoveryProbe Metabolism-related Compound Library: Applied
2026-07-07
The DiscoveryProbe™ Metabolism-related Compound Library uniquely empowers metabolic and antiviral research by offering 493 well-characterized, cell-permeable small molecules. Its ready-to-use format streamlines high-throughput metabolic enzyme screening and pathway elucidation in both classic and cutting-edge experimental models.
Polygodial as a TRPA1 Channel Activator: Workflow & Insights
2026-07-07
Polygodial delivers targeted, reproducible activation of TRPA1 channels, streamlining experimental workflows in sensory neuron and epithelial signaling research. Its rapid solubility and reliable performance make it a top choice for dissecting membrane transporter pathways and neurophysiological mechanisms.
508 records 15/34 page Previous Next First page 上5页 1112131415 下5页 Last page